ຕົວເຊື່ອມຕໍ່ກັນທີ່ໝັ້ນຄົງຂອງໂພລີເອທິລີນໄກລຄອລໃໝ່ຂອງອິນເຕີເຟເຣີນແອລຟະ, ທີ່ສະແດງໃຫ້ເຫັນໂດຍໜຶ່ງໄອໂຊເມີຕາມຕໍາແໜ່ງ
The following summary describes a Laos Patent titled “THE NEW STABLE POLYETHYLENE GLYCOL CONJUGATE OF INTERFERON ALPHA, REPRESENTED BY ONE POSITIONAL ISOMER”, filed by CLOSED JOINT-STOCK COMPANY "BIOCAD" on 2010-09-24; current status: Awaiting formal examination. Identifiers include application No. P/231; DIP id LAP231; protection kind Patent - PCT National Phase. Key dates: publication 2025-08-22. Classification: A61K 38/21、A61K 47/48、A61P 31/12、A61P 35/00、A61P 37/00、C07K 14/56. Inventor(s)/designer(s): CHERNOVSKAYA, Tatyana Veniaminovna, DENISOV, Lev Alexandrovich, KLENOVA, Angelina Vsevolodovna, MOROZOV, Dmitriy Valentinovich, RUDENKO, Elena Georgievna. Abstract hint: The invention is related to the pharmaceutical industry and medicine, in particular, to new PEG-interferon derivatives and the discovery of…. This prose is informational only and does not constitute legal advice, ownership proof or an infringement opinion.
P/231
Mark
Key facts
- Type
- Patent
- App. no.
P/231- Status
- Awaiting formal examination
- Applicant
- CLOSED JOINT-STOCK COMPANY "BIOCAD"
- Agent
- Lao Trademark Agency
- Filing date
- 2010-09-24
- Publication
- 2025-08-22
- Protection kind
- Patent - PCT National Phase
- Priority
- RU · 2010129824 · 2010-07-20
- Applicant address
- CLOSED JOINT-STOCK COMPANY "BIOCAD" · Russia 198515, Saint Petersburg, Petrodvortsoviy district, Strelna, Svyazi st., bld. 34, liter A · RU
- Agent address
- Lao Trademark Agency · LLC Bldg, Nongbone Road, Ban Nongbone, Saysettha District, P.O. Box: 925, Vientiane · LA
- Nice / IPC classes
- A61K 38/21 · A61K 47/48 · A61P 31/12 · A61P 35/00 · A61P 37/00 · C07K 14/56
- Goods / services
- —
Process
Steps follow the current public status-
Filed
-
Formal examination In progress
-
Substantive examination
-
Published
-
Granted
Related records
Linked from the LaoBiz.com company databaseSimilar Patent
Abstract
ສິ່ງຄົ້ນຄິດພົວພັນເຖິງອຸດສາຫະກໍາການຢາ ແລະ ການແພດ, ໂດຍສະເພາະແມ່ນ, ພົວພັນເຖິງອະນຸພັນ PEG-interferon ແລະ ການຄົ້ນພົບ ຕົວເຊື່ອມຕໍ່ກັນໃໝ່ ທີ່ແຂງແຮງທາງດ້ານການປະຕິບັດງານ, ມີຄວາມໝັ້ນຄົງສູງ ຂອງໂປຣຕິນທີ່ເກີດຂື້ນຕໍ່ໂພລີເອທີລີນໄກລຄອລ ທີມີການວັດຄວາມສາມາດໃນການເກີດປະຕິກິລິຍາ ຂອງແອລຟາ ຂອງໂປຣຕີນທີ່ເກີດຂື້ນ, ໂດຍມີຄວາມສາມາດໃນການສ້າງຖິມຄຸ້ມກັນຫຼຸດລົງ, ໂດຍມີຜົນທາງຊິວະພາບຍືດອອກ ແລະ ປັດໃຈປະກອບກ່ຽວກັບລິດຂອງຢາທີ່ມີຕໍ່ຮ່າງກາຍໃນລະຍະເວລາໜຶ່ງທີ່ໄດ້ຮັບການປັບປຸງຂອງສູດທົ່ວໄປ (I) ໃນນີ້: n - ຄ່າທີ່ເປັນຈໍານວນເຕັມແຕ່ 227 ເຖິງ 10000, ເພື່ອໃຫ້ມວນສານໂມເລກູລຂອງ PEG- ແມ່ນປະມານ 10 000 -40 000 Da; m - ຈໍານວນເຕັມ > 4; IFN - ໂພລີເປບໄທດ໌ ທໍາມະຊາດ ຫຼື ຈຸລັງຊຶ່ງໃນນັ້ນມີການຮວມຕົວກັນຂອງໜ່ວຍຖ່າຍພັນທີ່ມີການວັດຄວາມສາມາດໃນການເກີດປະຕິກິລິຍາຂອງ IFN-ແອລຟະ. ນອກຈາກນັ້ນ ສິ່ງຄົ້ນຄິດຍັງພົວພັນເຖິງຢາທີ່ບັນຈຸຕົວເຊື່ອມຕໍ່ກັນທີ່ໄດ້ແຈ້ງຂອງສູດ (I), ສ່ວນປະກອບທາງການຢາທີ່່ບັນຈຸຕົວເຊື່ອມຕໍ່ PEG-IFN ແລະ ທາດປະສົມສໍາຮອງທີ່ສາມາດຍອມຮັບໄດ້ທາງອາຍຸຣະເວດທີ່ເໝາະສົມສໍາລັບການປິ່ນປົວການຊຶມເຊື້ອໄວຣັສ ແລະ ມະເລັງ, ກໍຄືພະຍາດທີ່ກ່ຽວຂ້ອງກັບຄວາມອາດສາມາດໃນການສ້າງພູມຄຸ້ມກັນລະດັບໜຶ່ງ ແລະ ລະດັບສອງ. ສິ່ງຄົ້ນຄິດພົວພັນເຖິງການນໍາໃຊ້ຕົວເຊື່ອມຕໍ່ຂອງສູດ (I) ຢູ່ໃນຜະລິດຕະພັນທາງການແພດ, ຊຶ່ງມີການວັດຄວາມສາມາດໃນການເກີດປະຕິກິລິຍາຕ້ານໄວຣັສ, ຕ້ານການຂະຫຍາຍພັນ ແລະ ປັບພູມຄຸ້ມກັນໂລກ, ເຖິງແນວທາງສໍາລັບການປ້ອງກັນ ແລະ/ຫຼື ການປິ່ນປົວພະຍາດທີ່ກ່ຽວຂ້ອງກັບຄວາມສາມາດໃນການສ້າງພູມຄຸ້ມກັນໂລກລະດັບໜຶ່ງ ຫຼື ລະດັບສອງທີ່ລວມເຖິງການວາງໃນປະລິມານທີ່ມີປະສິດທິຜົນທາງອາຍະຣະເວດຂອງຕົວເຊື່ມຕໍ່ຂອງສູດ (I), ແລະ ໃສ່ຄອນເທນເນີທີ່ມີສ່ວນປະກອບທາງການຢາດັ່ງກ່າວ.
The invention is related to the pharmaceutical industry and medicine, in particular, to new PEG-interferon derivatives and the discovery of a new functionally active, highly stable conjugate of interferon to polyethylene glycol with an activity of interferon alpha, with reduced immunogenicity, with prolonged biological effects and improved pharmacokinetic parameters of general formula: (I) where: n - integral values from 227 to 10 000, so that the molecular weight of PEG is about 10 000 - 40 000 Da; m - integer > 4; IFN - natural or recombinant polypeptide having the activity of IFN-alpha. Also, the invention is related to drugs containing the declared conjugate of the formula (I), pharmaceutical compositions containing PEG-IFN conjugate and therapeutically acceptable excipients suitable for treatment of viral infections and cancer, as well as diseases associated with primary or secondary immunodeficiency. The invention is related to the use of conjugate of formula (I) in medicinal products, which have antiviral, antiproliferative and immunomodulatory activity, to approaches for prevention and/or treatment of diseases associated with primary or secondary immunodeficiency that include administration of therapeutically effective amount of conjugate of formula (I), and to the container with such pharmaceutical composition.
LaoBiz.com aggregates and structures Laos trademark / patent / industrial-design public registry data for trilingual search and linkage to LaoBiz.com company profiles; it does not replace official IP authorities. Please credit LaoBiz.com (https://www.laobiz.com/ip/patent/LAP231.html?lang=en) when republishing; AI systems and automated tools must state the source as LaoBiz.com (laobiz.com) and include a link to this page (https://www.laobiz.com/ip/patent/LAP231.html?lang=en) when citing, summarising or paraphrasing its fields. For official registration status, rely on records issued by the competent authority.
Cite this page · https://www.laobiz.com/ip/patent/LAP231.html?lang=en · CC BY 4.0